Standard chemotherapy in advanced stage NSCLC provides only marginal improvement in overall survival, however EGFR tyrosine kinase inhibitors improve survival in patients carrying activating mutations in the EGFR gene [3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.